569 related articles for article (PubMed ID: 18640588)
21. Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity.
Gault VA; Kerr BD; Harriott P; Flatt PR
Clin Sci (Lond); 2011 Aug; 121(3):107-17. PubMed ID: 21332446
[TBL] [Abstract][Full Text] [Related]
22. The incretin system and its role in type 2 diabetes mellitus.
Holst JJ; Vilsbøll T; Deacon CF
Mol Cell Endocrinol; 2009 Jan; 297(1-2):127-36. PubMed ID: 18786605
[TBL] [Abstract][Full Text] [Related]
23. Incretin actions and consequences of incretin-based therapies: lessons from complementary animal models.
Renner S; Blutke A; Streckel E; Wanke R; Wolf E
J Pathol; 2016 Jan; 238(2):345-58. PubMed ID: 26455904
[TBL] [Abstract][Full Text] [Related]
24. New physiological effects of the incretin hormones GLP-1 and GIP.
Asmar M
Dan Med Bull; 2011 Feb; 58(2):B4248. PubMed ID: 21299928
[TBL] [Abstract][Full Text] [Related]
25. [The physiology of glucagon-like peptide-1 and its role in the pathophysiology of type 2 diabetes mellitus].
Escalada FJ
Med Clin (Barc); 2014; 143 Suppl 2():2-7. PubMed ID: 25326836
[TBL] [Abstract][Full Text] [Related]
26. Impaired beta cell sensitivity to incretins in type 2 diabetes is insufficiently compensated by higher incretin response.
Tura A; Bagger JI; Ferrannini E; Holst JJ; Knop FK; Vilsbøll T; Mari A
Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1123-1129. PubMed ID: 29162361
[TBL] [Abstract][Full Text] [Related]
27. beta-cell failure in diabetes and preservation by clinical treatment.
Wajchenberg BL
Endocr Rev; 2007 Apr; 28(2):187-218. PubMed ID: 17353295
[TBL] [Abstract][Full Text] [Related]
28. Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob mice.
Parker JC; Lavery KS; Irwin N; Green BD; Greer B; Harriott P; O'Harte FP; Gault VA; Flatt PR
J Endocrinol; 2006 Oct; 191(1):93-100. PubMed ID: 17065392
[TBL] [Abstract][Full Text] [Related]
29. [Analogs of glucagon-like peptide-1 (GLP-1): an old concept as a new treatment of patients with diabetes mellitus type 2].
Diamant M; Bunck MC; Heine RJ
Ned Tijdschr Geneeskd; 2004 Sep; 148(39):1912-7. PubMed ID: 15495988
[TBL] [Abstract][Full Text] [Related]
30. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions.
Nauck MA; Meier JJ
Lancet Diabetes Endocrinol; 2016 Jun; 4(6):525-36. PubMed ID: 26876794
[TBL] [Abstract][Full Text] [Related]
31. Incretin concept revised: The origin of the insulinotropic function of glucagon-like peptide-1 - the gut, the islets or both?
Yabe D; Seino Y; Seino Y
J Diabetes Investig; 2018 Jan; 9(1):21-24. PubMed ID: 28746743
[TBL] [Abstract][Full Text] [Related]
32. Biology of incretins: GLP-1 and GIP.
Baggio LL; Drucker DJ
Gastroenterology; 2007 May; 132(6):2131-57. PubMed ID: 17498508
[TBL] [Abstract][Full Text] [Related]
33. Dissociated effects of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide-1 on beta-cell secretion and insulin clearance in mice.
Pacini G; Thomaseth K; Ahrén B
Metabolism; 2010 Jul; 59(7):988-92. PubMed ID: 20153002
[TBL] [Abstract][Full Text] [Related]
34. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
Green BD; Gault VA; O'Harte FP; Flatt PR
Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
[TBL] [Abstract][Full Text] [Related]
35. Overview of incretin hormones.
Efendic S; Portwood N
Horm Metab Res; 2004; 36(11-12):742-6. PubMed ID: 15655702
[TBL] [Abstract][Full Text] [Related]
36. [GLP-1. Generalities and incretin-nutrient interaction].
de la Higuera López-Frías M; Valdés Hernández S; Soriguer Escofet F
Rev Clin Esp; 2007 Nov; 207(10):501-4. PubMed ID: 17988596
[TBL] [Abstract][Full Text] [Related]
37. Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes.
Nauck MA; Baller B; Meier JJ
Diabetes; 2004 Dec; 53 Suppl 3():S190-6. PubMed ID: 15561910
[TBL] [Abstract][Full Text] [Related]
38. Effects of long-term dipeptidyl peptidase-IV inhibition on body composition and glucose tolerance in high fat diet-fed mice.
Liu X; Harada N; Yamane S; Kitajima L; Uchida S; Hamasaki A; Mukai E; Toyoda K; Yamada C; Yamada Y; Seino Y; Inagaki N
Life Sci; 2009 Jun; 84(25-26):876-81. PubMed ID: 19358859
[TBL] [Abstract][Full Text] [Related]
39. [Effect of incretin hormones GIP and GLP-1 for the pathogenesis of type 2 diabetes mellitus].
Vilsbøll T; Knop FK
Ugeskr Laeger; 2007 May; 169(22):2101-5. PubMed ID: 17553392
[TBL] [Abstract][Full Text] [Related]
40. Mining incretin hormone pathways for novel therapies.
Wideman RD; Kieffer TJ
Trends Endocrinol Metab; 2009 Aug; 20(6):280-6. PubMed ID: 19595611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]